Pharma manufacturers may need to upgrade their coupon programs to accommodate for the emergence of copay accumulators and related benefit mechanisms.
Taking a closer look at the evolving legal treatment of coupons and copay accumulators.
Significant uncertainty surrounds the future of drug pricing reform, causing industry observers to take a closer look at the policy views of the president-elect, state and Congressional lawmakers, and the general public.
The practice’s emerging-if improbable-cost-saving potential.
Just as insurers and regulators have sought to tamp down compounding costs and utilization, observers have begun to acknowledge that the practice may serve as an antidote to spiraling drug prices. John S. Linehan reports.